Helsinki University Hospital - Meilahti Vaccine Research Center

The Meilahti Vaccine Research Center is advancing research in the therapeutic area of Virus Diseases, concentrating on COVID-19 in non‑hospitalized adults and adolescents who are at high risk of severe outcomes. The study evaluates a novel antiviral compared with placebo to determine its ability to prevent disease progression.

• Evaluation of antiviral efficacy in high‑risk patients
• Safety monitoring and tolerability assessment
• Impact on rates of hospitalization and severe illness

Helsinki University Hospital hosts two investigators conducting this trial, contributing to the broader effort to improve COVID‑19 treatment options across Europe.

In the area of Bacterial Infections and Mycoses, the center is studying Group B streptococcus (GBS) disease through a maternal vaccination program. The investigational vaccine GBS6 is being tested for safety, tolerability, and the ability to generate protective antibodies in both pregnant participants and their infants.

• Safety and tolerability of the vaccine in pregnant women
• Assessment of maternal immunization benefits for newborns
• Measurement of anti‑CPS IgG levels predicting protection against early‑onset disease
• Evaluation of predicted efficacy across six serotypes for late‑onset disease

The site’s two trials, overseen by three investigators, aim to reduce invasive GBS infections and support maternal‑infant health worldwide.